Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2013-05-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
关于签订日常经营重大合同的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a significant daily operation contract between the company 嘉事堂药业股份有限公司 and 首钢总公司. It details the contract parties, contract content, cooperation terms, financial impact, risk warnings, and contract approval procedures. There is no financial statement or report data included, nor is it a transcript, presentation, or voting result. The document is a formal public announcement of a major contract signing, which fits best under a general regulatory announcement category. It is not an annual or interim report, audit report, or any other specific financial filing. Given the content and length (3379 characters), it is not a report publication announcement but a regulatory filing about a material contract.
2013-05-20 Chinese
2012年企业社会责任报告
Environmental & Social Information Classification · 95% confidence The document is titled "2012 年企业社会责任报告" (2012 Corporate Social Responsibility Report) and includes detailed sections on the company's social responsibility activities, governance, management, environmental and social practices, and stakeholder communication. It references compliance with social responsibility guidelines and covers economic, environmental, and social responsibility aspects for the year 2012. The content is comprehensive and focused on ESG (Environmental, Social, and Governance) factors rather than financial results or regulatory filings. Therefore, this document fits the category of Environmental & Social Information (SR). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or summary.
2013-05-14 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding by the information disclosure obligor (银谷控股集团有限公司) in 嘉事堂药业股份有限公司, including the number of shares held before and after the change, the nature of the shareholding change, and related declarations. The document references relevant securities laws and regulations governing shareholding disclosures. It does not contain financial statements or earnings data, nor is it an announcement of a report publication. It is a notification of a change in major shareholding levels, consistent with the definition of Major Shareholding Notification (MRQ). The document length is 4202 characters, which is sufficient for a detailed shareholding change report rather than a brief announcement or certification. Therefore, the appropriate classification is MRQ.
2013-05-13 Chinese
关于股东进行约定购回式证券交易的提示性公告
Transaction in Own Shares Classification · 95% confidence The document is a short announcement (1040 characters) regarding a shareholder's securities transaction involving a repurchase agreement. It details the transaction specifics, shareholder holdings before and after the transaction, and compliance with relevant regulations. There is no financial report, earnings data, or management discussion. The content fits the category of a transaction involving shares by a shareholder, specifically a repurchase agreement. This matches the description of 'Transaction in Own Shares' filings, which cover share repurchase or issuance activities. The document is not a full financial report or an announcement of a report, but a regulatory disclosure of a share transaction by a shareholder. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2013-05-13 Chinese
第四届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by 嘉事堂药业股份有限公司. It details the approval of a project delay related to the medical logistics phase three construction project, including voting results and independent director opinions. There is no financial data, earnings information, or detailed report content. The document is an announcement of a board decision, specifically about project timeline adjustment, which fits the category of Board/Management Information (MANG). The document length is short and focused on a board resolution, not a full report or financial statement.
2013-05-08 Chinese
关于医药物流三期建设项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the delay of a specific capital investment project (the pharmaceutical logistics phase three construction project). It details the original and revised timelines, reasons for the delay, financial impact on the project budget, and approvals from the board and supervisory committee. It references the use of raised funds from a prior public offering and includes independent director and sponsor opinions confirming compliance with regulatory requirements. The document is not a full financial report, audit report, or earnings release, but rather a regulatory announcement about a capital project delay and its impact on the use of raised funds. It fits best under Capital/Financing Update (CAP) as it concerns updates on the company's fundraising project and capital expenditure progress.
2013-05-08 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.